Skip to main content

Glycomics Market COVID – 19 Updated Analysis By Top Key Players – Merck KGaA , Agilent Technologies, Shimadzu Corporation, Thermo Fisher Scientific

The growth of this market is majorly driven by the increasing research activities on glycomics, rising R&D investments in pharmaceutical and biotechnology companies, growth in the proteomics market. On the other hand, emerging countries such as India and China providing lucrative opportunities for players operating in this segment.

The global glycomics market is estimated to grow from USD 1.0 billion in 2020 to USD 2.0 billion by 2025, at a CAGR of 13.8%.

Glycomics / Glycobiology Market by Product (Enzymes (Glycosyltransferase, Glycosidase), Instruments (Mass Spectrometry, Chromatography), Carbohydrates, Reagents & Chemicals), Application (Disease Diagnostics), End-User (Academic) -Global Forecasts to 2025

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=132685525


The Global Glycomics / Glycobiology Market is Segmented on:
1. Product
2. Instruments
3. Application
4. End User

The demand for glycomics products for drug discovery & development is estimated to grow at a high rate during the forecast period
Based on application, the glycomics market is segmented into drug discovery & development, disease diagnostics, and other applications. Drug discovery & development is the largest and the fastest-growing application segment in the market, majorly due to the increasing R&D investments in pharmaceutical and biotechnology companies and the growing number of drug discovery research activities in academic research institutes.

Enzymes segment accounted for the largest share of the glycomics market, by product, in 2019
The market is categorized into five product segments, namely, enzymes, instruments, kits, carbohydrates, and reagents & chemicals. The enzymes segment is expected to dominate the market in 2020 and is projected to grow at the highest CAGR during the forecast period. The large share and high growth of this segment can be attributed to the consumable nature of enzymes and their wide applications in a variety of R&D and drug discovery procedures.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132685525

Regional Analysis:

The global glycomics market is segmented into North America (US and Canada), Europe (Germany, the UK, France, Italy, Spain, and the Rest of Europe), Asia Pacific (Japan, China, India, Australia, and the Rest of Asia Pacific), and the Rest of the World (Latin America and the Middle East and Africa). In 2020, North America is expected to dominate the global market, followed by Europe.

Key Players:

Merck KGaA (Germany), Agilent Technologies (US), Thermo Fisher Scientific (US), New England Biolabs (US), Shimadzu Corporation (Japan), Takara Bio (Japan), S-BIO (subsidiary of Sumitomo Bakelite Co. Ltd., Japan), Waters Corporation (US), Asparia Glycomics S.L. (Spain), Bio-Techne (US), Bruker Corporation (US), Danaher Corporation (US), RayBiotech (US), Z Biotech (US), Chemily Glycoscience (US), Dextra Laboratories (UK), Lectenz Bio (US), and Ludger Ltd. (UK)

Labels:

Comments

Post a Comment

Popular posts from this blog

Autoinjectors Market | Newest Industry Data, Future Trends and Forecast 2023

Autoinjectors are used to self-administer drugs for the treatment of various diseases and conditions, such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis. Autoinjectors are easy to use, portable, and improve dosing accuracy, making them one of the most popular methods for the self-administration of drugs. The  global autoinjectors market  is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023). In terms of Therapy, the global autoinjectors market can be segmented into: Rheumatoid Arthritis Multiple Sclerosis Diabetes Anaphylaxis Other Therapies (Cardiovascular Diseases, Migraines, Psoriasis, and Anemia) By therapy, the rheumatoid arthritis segment is expected to account for the largest share of the market in 2018 On the basis of therapy, the autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therap...
Post a Comment
Read more

Healthcare BPO Market To Reach $312.43 Billion By 2022 : Increasing Consolidation In The Healthcare Industry

  What This Report Will Provide? In the current market scenario, there is a growing demand for healthcare BPO services. The objective of this report is to define, describe, and forecast the market on the basis of outsourcing services including payer, provider, and pharmaceutical services and region. It provides detailed information regarding the major factors influencing the growth of healthcare outsourcing market. This report also tracks and analyzes competitive developments of the key players in terms of market developments, product portfolios, and financials. Expected Revenue Growth: Healthcare BPO market  is estimated to grow at a CAGR of 10.2% from 2017 to 2022 to reach $312.43 billion by 2022 from $191.68 billion in 2017. The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022. Major Growth Boosters: Patent cliffs, complex clinical trial protocols, and new reporting requirements are forcing pha...
Post a Comment
Read more

North American Nuclear Medicine Market To Reach USD 2.7 Billion By 2024 – Expansion In Emerging Economies

  What This Report Will Provide? The study involved four major activities in estimating the current size for the North American nuclear medicine market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Expected Revenue Growth: [159 Pages Report] The  North American nuclear medicine market  is expected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, growing at a CAGR of 4.1% during the forecast period. Major Growth Boosters: Growth in the market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer & cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment...
Post a Comment
Read more